Benign Conditions

In the pivotal phase 3 DAPA-CKD trial, dapagliflozin reduced the relative risk of worsening of renal function, onset of end-stage kidney disease, or cardiovascular or renal death by 39%.

The FDA’s decision not to approve roxadustat follows a vote from the agency’s Cardiovascular and Renal Drugs Advisory Committee that the drug’s benefit-risk profile does not support approval.

The FDA has issued a complete response letter regarding a new drug application for tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.

The mechanism of action of roxadustat differs from that of erythropoietin stimulating agents.

Lumasiran is the first drug approved by the FDA for the treatment of patients with primary hyperoxaluria type 1.

The application for the targeted release formulation of budesonide is supported by data from the phase 3 NefIgArd trial and the phase 2 NEFIGAN trial.

The retrospective study compared reintervention rates in the 4 standard surgical interventions for lower urinary tract symptoms due to benign prostatic obstruction.

Minimally-invasive treatment with the iTind device (Medi-Tate) provides rapid and sustained improvement of LUTS in men with BPH, without adversely affecting patients’ sexual function, according to a recently published 12-month study.

Lobe enucleation efficiency is significantly better with Moses technology, investigators report.

On the latest episode of the Speaking of Urology podcast, Dr. Giulia Lane discusses her recent study evaluating treatment of urethral stricture disease in women.

Compared with the open procedure, robot-assisted simple prostatectomy was associated with a shorter median hospital stay.

Experts in prostate cancer, bladder cancer, kidney stones, OAB/incontinence, BPH, and sexual dysfunction recap all the key advances from 2020.

Next-generation DNA sequencing can identify more than 50,000 microorganisms.

Bradley A. Erickson, MD, MS, discusses what he and his co-authors learned from developing a mobile app for assessing urologic chronic pelvic pain syndrome.

Investigators reported that the treatment-emergent adverse event results showed combination tamsulosin and mirabegron was well-tolerated and had a favorable safety profile.

The Optilume drug-coated balloon catheter system has been approved for use in European patients with urethral strictures.

Julia Beth Finkelstein, MD, MPH, CPPS, and colleagues evaluated the safety and costs associated with telemedicine appointments for pediatric urologic patients.

The drug-coated balloon catheter system is being compared with a sham device in a double-blinded randomized trial.

Minimally invasive water vapor thermal therapy offers rapid improvements in LUTS, QoL, and flow rate that remain durable to 5 years in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Retreatment rates were low with both aquablation and transurethral resection of the prostate.

In this interview, Jeffrey Weiss, MD, also describes “most exciting area in nocturia research.”

In this interview with Urology Times® Editorial Consultant Gopal Badlani, MD, Weiss also stresses the importance of a 24-hour voiding diary.

The Soltive Laser System, which uses thulium fiber laser technology, has been shown to generate finer particulate and dusted stones in half the time as a standard holmium yttrium aluminium garnet laser.

Alan W. Shindel, MD, provides an expert summary and analysis of the 2020 AUA Guidelines for Disorders of Ejaculation.

The reduction in urinary urgency incontinence episodes observed was “quite significant,” an investigator said.